Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 8/20 | 0.42 |
| ▸ | HTR1D | P28221 | 7/20 | 0.42 |
| ▸ | HTR1B | P28222 | 5/20 | 0.42 |
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.42 |
| ▸ | HTR3B | O95264 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | HTR5A | P47898 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.42 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6552882 | 1.00 | HTR1A (0.42) | HTR1AHTR1DHTR1BHTR2AHTR3E | |
| SCHEMBL6552879 | 1.00 | HTR1A (0.42) | HTR1AHTR1DHTR1BHTR2AHTR3E | |
| SCHEMBL6552931 | 0.90 | HTR5A (0.46) | HTR1AHTR1DHTR1BHTR2AHTR3E | |
| SCHEMBL6552932 | 0.90 | HTR5A (0.46) | HTR1AHTR1DHTR1BHTR2AHTR3E | |
| SCHEMBL6553062 | 0.90 | HTR5A (0.46) | HTR1AHTR1DHTR1BHTR2AHTR3E | |
| SCHEMBL6551557 | 0.86 | PRKCQ (0.44) | HTR1AHTR1DHTR1BHTR2AHTR3E | |
| SCHEMBL4247868 | 0.83 | HTR6 (0.61) | HTR1AHTR1DHTR1BHTR2AHTR3E | |
| SCHEMBL4244446 | 0.83 | HTR6 (0.61) | HTR1AHTR1DHTR1BHTR2AHTR3E | |
| SCHEMBL4244450 | 0.83 | HTR6 (0.61) | HTR1AHTR1DHTR1BHTR2AHTR3E | |
| SCHEMBL6811778 | 0.83 | PRKCQ (0.46) | HTR1AHTR1DHTR1BHTR2AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7335660-B2 | Isochroman compounds for treatment of CNS disorders | ELI LILLY AND COMPANY (US) | 2008-02-26 | — | — | US | disclosed |
| CN-1312148-C | Isochroman compounds for treatment of CNS disorders | LILLY CO ELI (US) | 2007-04-25 | — | — | CN | disclosed |
| EP-1458703-B1 | ISOCHROMAN COMPOUNDS FOR TREATMENT OF CNS DISORDERS | LILLY CO ELI (US) | 2007-02-28 | — | — | EP | disclosed |
| CN-1620447-A | Isochroman compounds for treatment of cns disorders | LILLY CO ELI (US) | 2005-05-25 | — | — | CN | disclosed |
| US-20050014750-A1 | Isochroman compounds for treatment of cns disorders | ELI LILLY AND COMPANY | 2005-01-20 | — | — | US | disclosed |
| EP-1409476-B1 | PHARMACEUTICAL COMPOUNDS WITH SEROTONIN RECEPTOR ACTIVITY | LILLY CO ELI (US) | 2004-12-15 | — | — | EP | disclosed |
| EP-1458703-A1 | ISOCHROMAN COMPOUNDS FOR TREATMENT OF CNS DISORDERS | ELI LILLY AND COMPANY (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20040180883-A1 | Pharmaceutical compounds with serotonin receptor activity | GILMORE JEREMY (GB) | 2004-09-16 | — | — | US | disclosed |
| US-20040122001-A1 | Pharmaceutical compounds | ELI LILLY AND COMPANY | 2004-06-24 | — | — | US | disclosed |
| EP-1409476-A1 | PHARMACEUTICAL COMPOUNDS WITH SEROTONIN RECEPTOR ACTIVITY | ELI LILLY AND COMPANY (US) | 2004-04-21 | — | — | EP | disclosed |
| EP-1345930-A2 | PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2003-09-24 | — | — | EP | disclosed |
| WO-2003053948-A1 | ISOCHROMAN COMPOUNDS FOR TREATMENT OF CNS DISORDERS | ELI LILLY AND COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
| WO-2003006455-A1 | PHARMACEUTICAL COMPOUNDS WITH SEROTONIN RECEPTOR ACTIVITY | ELI LILLY AND COMPANY (US) | 2003-01-23 | — | — | WO | disclosed |
| WO-2002050067-A2 | PHARMACEUTICAL HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180883-A1 | Pharmaceutical compounds with serotonin receptor activity | HTR1A, HTR5A, HTR1E | HTR1A 1/4885HTR1D 8/4885HTR1B 9/4885 |
| US-20050014750-A1 | Isochroman compounds for treatment of cns disorders | INA, CNR2, CNR1 | HTR1A 192/4885HTR1D 201/4885HTR1B 185/4885 |
| US-20040122001-A1 | Pharmaceutical compounds | CYP2D6, LPXN, CYP1B1 | HTR1A 264/4885HTR1D 124/4885HTR1B 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.